In both studies , olodaterol 5 g and 10 g significantly improved the FEV1 AUC0-3 response ( P < 0.0001 ) and trough FEV1 ( study 1222.11 , P < 0.0001 ; study 1222.12 , P < 0.05 , post hoc ) at week 12 , with an incidence of adverse events comparable with that of placebo .